An investigational, oral COVID-19 antiviral candidate reduced the risk of hospitalization or death by 89% in an interim analysis
An investigational oral antiviral candidate consisting of PF-07321332 plus ritonavir (Paxlovid™) significantly reduced hospitalization and death in non-hospitalized adult patients with COVID-19 at high risk of progressing to severe illness. An interim analysis of the phase 2/3 EPIC-HR trial showed an 89% reduction in the risk of COVID-19-associated hospitalization or death from any cause at day 28 in the antiviral group compared with the placebo group in patients treated within three days of symptom onset (0.8% vs 7.0%, respectively; P <.0001). Similar results were observed in patients treated within five days of symptom onset (1.0% vs 6.7%; P <.0001). No deaths were reported in patients who received the antiviral treatment compared with 10 deaths (1.6%) in patients who received placebo. Treatment-emergent adverse events were comparable between antiviral treatment (19%) and placebo (21%) groups and were mostly mild in intensity. Fewer serious adverse events (1.7% vs 6.6%) and discontinuation of the study drug due to adverse events (2.1% vs 4.1%) were observed in patients receiving the antiviral treatment compared with placebo, respectively.
Mahase E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021;375:n2713. Available at https://www.bmj.com/content/375/bmj.n2713